Insider Trading May 26, 2026 07:19 PM

Insider Selling at Amprius Technologies Amid Mixed Operational Signals

CTO sells stock following a year of significant price appreciation; company reports Q1 earnings and announces key industry collaboration.

By Maya Rios AMPX

Stefan Constantin Ionel, Chief Technology Officer at Amprius Technologies, Inc., sold $426,083 worth of common stock. This transaction occurred as the company's shares have experienced substantial gains over the past year, reaching a current trading price of $17.83. The article also details recent operational news, including Q1 2026 earnings that missed analyst estimates but exceeded revenue forecasts, alongside an announcement regarding a strategic partnership.

Insider Selling at Amprius Technologies Amid Mixed Operational Signals
AMPX

Key Points

  • The CTO's stock sale (selling $426,083 worth of shares) occurred despite a massive year-over-year increase in the company's share price.
  • Amprius Technologies exceeded revenue expectations ($28.5 million vs. $25.32 million forecast) during Q1 2026, though its net loss was below analyst projections.
  • The formation of a strategic partnership with Matternet to supply silicon anode lithium-ion batteries for drone delivery aircraft signals future commercial development.

Stefan Constantin Ionel, Chief Technology Officer at Amprius Technologies, Inc., executed a sale of company stock on May 21, 2026. The transaction involved the disposition of 28,812 shares of common stock, totaling $426,083.

This selling activity comes against a backdrop of significant price appreciation for Amprius Technologies (NASDAQ:AMPX) shares. Over the past year alone, AMPX shares have surged by 558%, with the stock currently trading near $17.83.

According to filing details, the sold shares were transacted at an average price of $14.7884 per share, falling within a narrow range of $14.54 and $15.08. The structure of the sale was described as non-discretionary, sell-to-cover arrangement. This specific mechanism was utilized to fund tax withholding obligations associated with the vesting of restricted stock units (RSUs).

Following this recent divestiture, Mr. Ionel's direct holdings in Amprius Technologies common stock amount to 804,518 shares. These total shares comprise 591,183 restricted stock units, which represent a contingent right for him to receive one share of common stock each, subject to specific vesting schedules and conditions.


In other operational news, Amprius Technologies released its Q1 2026 earnings report. The company reported a net loss of $5 million, equating to -$0.04 per share. This figure was below the consensus expectations set by analysts, who had projected a net loss of -$0.0278 per share.

Despite missing profit estimates, Amprius Technologies managed to surpass revenue forecasts. The company reported $28.5 million in revenue, which exceeded the anticipated figure of $25.32 million for the quarter.

This earnings disclosure came amidst scrutiny from short seller Manatee Research. That firm had previously issued allegations against Amprius Technologies, accusing the company of engaging in exaggerated order reporting and various disclosure irregularities. This report by Manatee Research was reportedly based on a month-long investigation that included interviews, site visits, and review of legal filings.

On a positive strategic note, Amprius Technologies announced a collaboration with Matternet. Under this partnership, the company will supply silicon anode lithium-ion batteries specifically designed for Matternet’s M2 drone delivery aircraft. This joint effort aims to develop advanced battery solutions tailored for Matternet’s next-generation platform, with volume production readiness targeted for early 2027.


The recent activities at Amprius Technologies illustrate a complex mix of market developments and strategic industry moves. The insider selling activity, coupled with the substantial price increase over the past year, contrasts with the operational report that shows both revenue exceeding expectations and net losses falling short of analyst predictions. This duality highlights ongoing internal adjustments alongside external growth opportunities within the sector.

Risks

  • Short seller allegations regarding exaggerated orders and disclosure irregularities cast a shadow over the company's reporting integrity. This impacts market trust and regulatory scrutiny.
  • The net loss reported in Q1 2026 ($5 million) remains a financial concern, despite strong top-line revenue performance, indicating ongoing operational costs or development expenses. This affects investor confidence and capital requirements.

More from Insider Trading

Rackspace Technology Executive Offloads Shares to Cover Tax Obligations Amid Stock Surge Jun 4, 2026 Fermi Inc. Executive Unloads $1M in Shares Amid Ongoing Corporate Restructuring Jun 4, 2026 Veracyte Executive Sells Nearly $700K in Shares Amid Product Rollouts and Analyst Upgrades Jun 4, 2026 Veracyte Executive Traces Share Disposition Amid Clinical Milestones and Valuation Scrutiny Jun 4, 2026 Veracyte CFO Executes $177K Stock Sale Amid Clinical Trial Updates and Analyst Revisions Jun 4, 2026